$134 Million is the total value of Saturn V Capital Management LP's 18 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 15.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $14,208,926 | +148.5% | 1,629,464 | +1.1% | 10.61% | +123.6% |
| CRNX | Buy | CRINETICS PHARMACEUTICALS IN | $11,901,151 | +5.0% | 741,043 | +18.8% | 8.89% | -5.5% |
| KDNY | Buy | CHINOOK THERAPEUTICS INC | $11,732,837 | +74.4% | 506,818 | +19.8% | 8.76% | +57.0% |
| HZNP | Buy | HORIZON THERAPEUTICS PLC | $10,828,543 | +90.6% | 99,217 | +43.4% | 8.09% | +71.6% |
| BIIB | Buy | BIOGEN INC(NSM) | $10,414,726 | +379.9% | 37,459 | +389.0% | 7.78% | +331.9% |
| CYTK | Buy | CYTOKINETICS INC | $9,954,758 | +24.8% | 282,886 | +43.6% | 7.44% | +12.4% |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS INC | $9,703,882 | +158.7% | 1,163,535 | +242.1% | 7.25% | +132.8% |
| MORF | Sell | MORPHIC HOLDING INC | $9,282,626 | +25.9% | 246,616 | -8.6% | 6.93% | +13.3% |
| KALV | Buy | KALVISTA PHARMACEUTICALS INC | $8,818,779 | +31.7% | 1,121,982 | +55.8% | 6.59% | +18.5% |
| ASND | Buy | ASCENDIS PHARMA A/S - ADRsponsored adr | $8,278,456 | +4.1% | 77,210 | +12.9% | 6.18% | -6.3% |
| APLS | Sell | APELLIS PHARMACEUTICALS INC | $8,123,963 | -13.7% | 123,165 | -42.0% | 6.07% | -22.3% |
| ITOS | Buy | ITEOS THERAPEUTICS INC | $6,541,687 | -6.9% | 480,653 | +40.5% | 4.89% | -16.2% |
| SAGE | Sell | SAGE THERAPEUTICS INC | $6,084,955 | +13.4% | 145,018 | -7.1% | 4.54% | +2.0% |
| FOLD | Sell | AMICUS THERAPEUTICS INC(NMS) | $2,864,414 | -41.5% | 258,288 | -54.4% | 2.14% | -47.3% |
| ARQT | Sell | ARCUTIS BIOTHERAPEUTICS INC | $1,960,387 | -77.7% | 178,217 | -63.4% | 1.46% | -79.9% |
| Sell | 2SEVENTY BIO INC | $1,756,318 | -82.2% | 172,188 | -74.9% | 1.31% | -84.0% | |
| Sell | ASTRIA THERAPEUTICS INC | $1,347,809 | -13.4% | 101,339 | -40.2% | 1.01% | -22.1% | |
| New | SCILEX HOLDING CO(NAS) | $85,198 | – | 10,390 | +100.0% | 0.06% | – | |
| TBPH | Exit | THERAVANCE BIOPHARMA INC | $0 | – | -141,339 | -100.0% | -1.11% | – |
| ALBO | Exit | ALBIREO PHARMA INC | $0 | – | -341,827 | -100.0% | -5.70% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CRINETICS PHARMACEUTICALS IN | 4 | Q3 2023 | 14.0% |
| CYMABAY THERAPEUTICS INC | 4 | Q3 2023 | 10.6% |
| CYTOKINETICS INC | 4 | Q3 2023 | 7.4% |
| KALVISTA PHARMACEUTICALS INC | 4 | Q3 2023 | 7.3% |
| HORIZON THERAPEUTICS PUB L | 4 | Q3 2023 | 8.1% |
| BIOGEN INC(NSM) | 4 | Q3 2023 | 7.8% |
| ASCENDIS PHARMA A/S - ADR | 4 | Q3 2023 | 6.6% |
| ITEOS THERAPEUTICS INC | 4 | Q3 2023 | 5.8% |
| MORPHIC HOLDING INC | 4 | Q3 2023 | 6.9% |
| BIOCRYST PHARMACEUTICALS INC | 4 | Q3 2023 | 7.2% |
View Saturn V Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-12 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-09 |
View Saturn V Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.